Free Cash Flow

Advanced Drainage Systems raises its dividend, reflecting robust financial health and a strategy balancing shareholder rewards with strategic growth investments.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

CFO Martin Fischer's reappointment secures leadership continuity, reinforcing Fresenius Medical Care's focus on financial discipline and long-term growth.

With a new $1 billion credit facility, Curtiss-Wright has the financial firepower to accelerate its 'Pivot to Growth' through strategic acquisitions.

Riding a wave of strong earnings, EuroDry invests $74M in eco-friendly vessels, betting on a green future for the recovering drybulk market.

Hormel Foods declared its 392nd dividend, but a high payout ratio and lagging stock have investors weighing its legendary reliability against current risks.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

ExchangeRight's latest fund sold out fast, signaling a major investor shift toward sophisticated tax-deferred strategies and recession-proof real estate.

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

Dubai-based robotics firm Micropolis AI is under scrutiny after a delayed annual report triggered a warning from the NYSE American exchange.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Fintech platform Relay secures $50M from General Catalyst to tackle small business cash flow crises. Here’s what it means for a struggling Main Street.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

EMS, backed by Wynnchurch Capital, acquires a key rival, signaling a strategic consolidation push in the booming U.S. aluminum distribution market.

Quince Therapeutics' drug LAM-001 posts strong Phase 2a data, showing meaningful functional gains for patients with severe pulmonary hypertension.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

Activist investor Corvex Management, citing a 13-year low stock price, demands the Premier Inn owner be sold, escalating a battle over the hotel giant's future.

Birchcliff Energy's AGM saw all directors re-elected, but a closer look at the votes reveals significant shareholder discontent over board and pay policies.